Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 8/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.41 |
| ▸ | BTK | Q06187 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523873 | 1.00 | FGFR2 (0.43) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL24458475 | 0.93 | FGFR2 (0.42) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL29552790 | 0.93 | FGFR2 (0.42) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL31523855 | 0.90 | FGFR2 (0.47) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL24458612 | 0.90 | FGFR2 (0.47) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL24458533 | 0.89 | BTK (0.45) | FGFR2BTKKDREGFRITK | |
| SCHEMBL31523835 | 0.89 | BTK (0.45) | FGFR2BTKKDREGFRITK | |
| SCHEMBL24458598 | 0.87 | ITK (0.46) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL31523906 | 0.83 | EGFR (0.40) | FGFR2FGFR4FGFR1BTKKDR | |
| SCHEMBL24458869 | 0.83 | EGFR (0.40) | FGFR2FGFR4FGFR1BTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |